(Q24234678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1 reference

title

Bile acids for primary sclerosing cholangitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

main subject

ascending cholangitis

0 references

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Goran Poropat

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Vanja Giljaca

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Davor Stimac

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Vanja Giljaca

2

0 references

publication date

19 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

CD003626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Bile acids for viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Review article: current management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Mechanisms of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Recent advances in the management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Small-duct primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Bile-acid-induced cell injury and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Current diagnosis and management of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Intragastric administration of ursodeoxycholic acid suppresses immunoglobulin secretion by lymphocytes from liver, but not from peripheral blood, spleen or Peyer's patches in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Bile acids for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

Incidence and mortality of primary sclerosing cholangitis in the UK: A population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003626.PUB2

21 January 2018

1 reference

12 December 2020

Bile acids, liver injury, and liver disease

1 reference

12 December 2020

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

12 December 2020

Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis

1 reference

12 December 2020

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

1 reference

12 December 2020

1 reference

12 December 2020

Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses

1 reference

12 December 2020

1 reference

12 December 2020

Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer

1 reference

12 December 2020

Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children

1 reference

12 December 2020

A revised natural history model for primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

12 December 2020

1 reference

12 December 2020

Endoscopic and surgical management of primary sclerosing cholangitis.

1 reference

12 December 2020

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

12 December 2020

Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis

1 reference

12 December 2020

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

12 December 2020

Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles

1 reference

12 December 2020

Is there a role for liver biopsy in primary sclerosing cholangitis?

1 reference

12 December 2020

Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study

1 reference

12 December 2020

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

12 December 2020

Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.

1 reference

12 December 2020

Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis

1 reference

12 December 2020

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

12 December 2020

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

12 December 2020

[Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid]

1 reference

12 December 2020

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

12 December 2020

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

12 December 2020

The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis

1 reference

12 December 2020

Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis

1 reference

12 December 2020

Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis

1 reference

12 December 2020

Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group

1 reference

12 December 2020

Sclerosing cholangitis: broad spectrum of radiographic features

1 reference

12 December 2020

10.1002/14651858.CD003626.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21249655%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

PMC publication ID

7163275

0 references

2 references

Consolidated OpenCitations Corpus – April 2017